Forbion of the Netherlands has co-led, along with Novartis Venture Fund, a $130 million Series B funding for a US company developing small molecule chaperones to correct the misfolding of proteins in cells – a cause of Alzheimer’s and other diseases. The developer, Protego Biopharma Inc of San Diego, US, is a clinical stage company whose lead product is poised to enter a trial in patients with primary amyloidosis, a disease affecting the heart and kidneys.
